381 related articles for article (PubMed ID: 26467630)
1. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
[TBL] [Abstract][Full Text] [Related]
2. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
Malm M; Heinimäki S; Vesikari T; Blazevic V
Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
[TBL] [Abstract][Full Text] [Related]
3. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.
Lappalainen S; Tamminen K; Vesikari T; Blazevic V
Hum Vaccin Immunother; 2013 Sep; 9(9):1991-2001. PubMed ID: 23777748
[TBL] [Abstract][Full Text] [Related]
5. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.
Tamminen K; Lappalainen S; Huhti L; Vesikari T; Blazevic V
PLoS One; 2013; 8(7):e70409. PubMed ID: 23922988
[TBL] [Abstract][Full Text] [Related]
6. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.
Blazevic V; Lappalainen S; Nurminen K; Huhti L; Vesikari T
Vaccine; 2011 Oct; 29(45):8126-33. PubMed ID: 21854823
[TBL] [Abstract][Full Text] [Related]
7. Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.
Tamminen K; Heinimäki S; Vesikari T; Blazevic V
J Immunol Res; 2020; 2020():3194704. PubMed ID: 32411793
[TBL] [Abstract][Full Text] [Related]
8. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
Malm M; Vesikari T; Blazevic V
Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
[TBL] [Abstract][Full Text] [Related]
10. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
[TBL] [Abstract][Full Text] [Related]
11. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
[TBL] [Abstract][Full Text] [Related]
12. Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in
Malm M; Diessner A; Tamminen K; Liebscher M; Vesikari T; Blazevic V
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31083495
[TBL] [Abstract][Full Text] [Related]
13. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
Malm M; Tamminen K; Vesikari T; Blazevic V
Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
[TBL] [Abstract][Full Text] [Related]
14. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
15. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice.
Wang X; Ku Z; Dai W; Chen T; Ye X; Zhang C; Zhang Y; Liu Q; Jin X; Huang Z
Vaccine; 2015 Oct; 33(43):5779-5785. PubMed ID: 26424606
[TBL] [Abstract][Full Text] [Related]
16. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
[TBL] [Abstract][Full Text] [Related]
17. Immunization of Mice by Rotavirus NSP4-VP6 Fusion Protein Elicited Stronger Responses Compared to VP6 Alone.
Afchangi A; Arashkia A; Shahosseini Z; Jalilvand S; Marashi SM; Roohvand F; Mohajel N; Shoja Z
Viral Immunol; 2018 Apr; 31(3):233-241. PubMed ID: 29185875
[TBL] [Abstract][Full Text] [Related]
18. Expression and purification of norovirus virus like particles in Escherichia coli and their immunogenicity in mice.
Huo Y; Wan X; Ling T; Wu J; Wang W; Shen S
Mol Immunol; 2018 Jan; 93():278-284. PubMed ID: 28802994
[TBL] [Abstract][Full Text] [Related]
19. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
Tamminen K; Malm M; Vesikari T; Blazevic V
Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
[TBL] [Abstract][Full Text] [Related]
20. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
Malm M; Tamminen K; Vesikari T; Blazevic V
Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
